Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANX NASDAQ:HOOK NASDAQ:IMMX NASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.75-3.8%$1.79$1.41▼$4.34$74.64M0.151.45 million shs471,963 shsHOOKHOOKIPA Pharma$1.15$1.16$0.81▼$1.65$14.18M0.8511,089 shs431 shsIMMXImmix Biopharma$8.52-3.2%$9.37$1.94▼$12.14$463.58M0.092.09 million shs2.32 million shsIMUXImmunic$13.39-6.2%$14.13$5.06▼$15.84$182.39M1.37163,927 shs155,709 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics0.00%+2.34%+1.74%-11.17%+4.17%HOOKHOOKIPA Pharma0.00%0.00%0.00%+4.55%+18.17%IMMXImmix Biopharma0.00%-16.88%-12.35%-13.50%+193.79%IMUXImmunic0.00%-11.68%-11.15%+52.14%+34.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.75-3.8%$1.79$1.41▼$4.34$74.64M0.151.45 million shs471,963 shsHOOKHOOKIPA Pharma$1.15$1.16$0.81▼$1.65$14.18M0.8511,089 shs431 shsIMMXImmix Biopharma$8.52-3.2%$9.37$1.94▼$12.14$463.58M0.092.09 million shs2.32 million shsIMUXImmunic$13.39-6.2%$14.13$5.06▼$15.84$182.39M1.37163,927 shs155,709 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics0.00%+2.34%+1.74%-11.17%+4.17%HOOKHOOKIPA Pharma0.00%0.00%0.00%+4.55%+18.17%IMMXImmix Biopharma0.00%-16.88%-12.35%-13.50%+193.79%IMUXImmunic0.00%-11.68%-11.15%+52.14%+34.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 2.67Moderate Buy$7.50328.57% UpsideHOOKHOOKIPA Pharma 0.00N/AN/AN/AIMMXImmix Biopharma 2.70Moderate Buy$20.71143.13% UpsideIMUXImmunic 3.00Buy$47.57255.28% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, HOOK, IMUX, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2026IMMXImmix Biopharma Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.007/17/2026IMMXImmix Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/1/2026GANXGain Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/30/2026GANXGain Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/18/2026IMMXImmix Biopharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/18/2026IMMXImmix Biopharma Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/17/2026IMMXImmix Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$19.006/9/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026IMUXImmunic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/27/2026GANXGain Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K1,492.75N/AN/A$0.48 per share3.65HOOKHOOKIPA Pharma$9.35M1.52N/AN/A$4.25 per share0.27IMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/AIMUXImmunicN/AN/AN/AN/A($0.55) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%8/7/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%8/14/2026 (Estimated)IMUXImmunic-$97.17M-$5.58N/AN/AN/AN/A-220.75%-132.04%8/6/2026 (Estimated)Latest IMMX, HOOK, IMUX, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026IMMXImmix Biopharma-$0.17N/AN/AN/AN/AN/A8/11/2026Q2 2026GANXGain Therapeutics-$0.14N/AN/AN/A$0.03 millionN/A8/6/2026Q2 2026IMUXImmunic-$1.1756N/AN/AN/AN/AN/A5/13/2026Q1 2026IMUXImmunic-$0.71-$1.08-$0.37-$1.08N/AN/A5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.024.694.69HOOKHOOKIPA PharmaN/A3.613.61IMMXImmix BiopharmaN/A8.758.75IMUXImmunicN/A4.924.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%HOOKHOOKIPA Pharma63.88%IMMXImmix Biopharma11.26%IMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipGANXGain Therapeutics4.15%HOOKHOOKIPA Pharma3.30%IMMXImmix Biopharma30.30%IMUXImmunic5.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2042.65 million40.88 millionOptionableHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableIMUXImmunic7013.62 million12.87 millionOptionableIMMX, HOOK, IMUX, and GANX HeadlinesRecent News About These CompaniesImmunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts3 hours ago | marketbeat.comImmunic to Participate in Investor Conferences in JulyJuly 9, 2026 | prnewswire.comImmunic Expands Equity Plan and Reelects Board DirectorsJune 29, 2026 | tipranks.comImmunic Adds Veteran Biopharma Leader to BoardJune 25, 2026 | theglobeandmail.comImmunic to Participate in Investor, Industry and Scientific Conferences in JuneJune 10, 2026 | prnewswire.comImmunic presents new vidofludimus calcium data at multiple sclerosis conferenceMay 28, 2026 | proactiveinvestors.comImmunic Highlights Positive Phase 2 CALLIPER MS DataMay 28, 2026 | tipranks.comImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple SclerosisMay 28, 2026 | prnewswire.comImmunic names Erik Lundgren as CEO as it advances Phase 3 MS trialsMay 27, 2026 | proactiveinvestors.comImmunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive OfficerMay 27, 2026 | prnewswire.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19, 2026 | proactiveinvestors.comAnalysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Immunic (IMUX)May 19, 2026 | theglobeandmail.comImmunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of DirectorsMay 19, 2026 | prnewswire.comImmunic (IMUX) Gets a Buy from LifeSci CapitalMay 18, 2026 | theglobeandmail.comIs Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?May 17, 2026 | finance.yahoo.comImmunic advances Phase 3 MS program, eyes topline data by year-endMay 13, 2026 | proactiveinvestors.comImmunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | prnewswire.comImmunic: Saved By A 200 Million Private PlacementMay 12, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Hinge Health, Inc. Class A (HNGE)May 8, 2026 | theglobeandmail.comImmunic to Participate in Investor and Medical Conferences in MayApril 30, 2026 | prnewswire.comImmunic Appoints Veteran Neurology Leader as Chief Medical OfficerApril 30, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, HOOK, IMUX, and GANX Company DescriptionsGain Therapeutics NASDAQ:GANX$1.75 -0.07 (-3.85%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.76 +0.00 (+0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.HOOKIPA Pharma NASDAQ:HOOKHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Immix Biopharma NASDAQ:IMMX$8.52 -0.28 (-3.18%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$8.85 +0.33 (+3.87%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Immunic NASDAQ:IMUX$13.39 -0.89 (-6.23%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$13.34 -0.05 (-0.41%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
